IntroductionStudies of the cognitive and behavioral factors of perpetuation and quality of life in patients with somatoform disorders are important for identifying targets for psychological interventions and risk groups (Piontek et al., 2018, Dehoust et al., 2017, Schaefer et al., 2012, Flasinski et al., 2020).ObjectivesTo reveal beliefs and behavior in patients with somatoform disorders associated severity of somatic complaints and poorer subjective well-being.Methods125 patients with somatoform disorders 17-68 years old filled Screening for Somatoform Symptoms (Rief, Hiller, 2003), Cognitions About Body And Health Questionnaire (Rief et al., 1998), Scale for the Assessment of Illness Behaviour (Rief, Ihle, Pigler, 2003), and Quality of Life Enjoyment and Satisfaction Questionnairie-18 (Ritsner et al., 2005).ResultsSeverity of somatoform symptoms is higher in patients with catastrophization of bodily sensations, autonomic sensations, belief in their bodily weakness, somatosensory amplification, scanning for bodily symptoms, and disturbances in daily activities due to illness (r=.18-.38, p<.05). Adjusting for the severity of somatoform symptoms, subjective well-being was lower in patients with higher belief in their bodily weakness and somatosensory amplification, autonomic sensations, expression of symptoms, and changes in daily activities due to illness (r=.21-.40, p<.05).ConclusionsThe results suggests that regardless of symptoms severity poorer quality of life in patients with somatoform disorders is associated with beliefs about body and body perception that could be addressed in psychotherapy.

Introduction Psychological interventions including group analysis (Leichsenring et al., 2015, Beutel et al., 2008) are effective with patients having somatoform disorders. Objectives To reveal differences in dynamics of pathological bodily sensations, quality of life, illness representation in patients with somatoform disorders undergoing group analysis and psychoeducation program. Methods 100 patients with somatoform disorders (undifferentiated somatoform disorder – 42, somatization disorder – 10, somatoform autonomic disfunction – 36, persistent somatoform pain disorder and other SD – 12) were randomly assigned randomized to psychoeducation intervention and to the group analysis psychotherapy. Before and after treatment they filled Screening for somatoforms symptoms (Rief, Hiller, 2003), Illness Perception Questionnaire - Revised (Moss-Morris et al., 2002), Cognitions About Body And Health Questionnaire (Rief et al., 1998), Scale for the Assessment of Illness Behaviour (Rief et al., 2003), Quality of Life Enjoyment and Satisfaction Questionnairie-18 (Ritsner et al., 2005). Results In both conditions decrease in complaints was the most in patients with undifferentiated somatoform disorder and the least in somatoform autonomic disfunction (F=6.19, p<.01, η²=.17). In patients with somatization disorder there was the most increase in quality of life in leisure time, beliefs about intolerance to bodily sensations, rechecking the diagnosis (F=3.32-4.87, p<.05, η²=.10-.14). Decrease in beliefs about bodily weakness, illness consequences was the most prominent in patients with somatization disorder undergoing group therapy (F=2.90-4.46, p<.05, η²=.09-.13). Conclusions Patients with undifferentiated somatoform disorder demonstrate most clinical improvement in interventions while patients with somatization disorder – the most psychological improvement. Research is supported by the Russian Foundation for Basic Research, project No. 20-013-00799. Disclosure Research is supported by the Russian Foundation for Basic Research, project No. 20-013-00799.

IntroductionCurrently, there are no ideal medications for treating anorexia nervosa (AN) and bulimia nervosa (BN). This is due to the variety of symptoms from the mental and somatic spheres.ObjectivesDescribe the modern methods of psychopharmacotherapy AN and BN.MethodsData from available publications on the topic of psychopharmacotherapy AN and BN, and long-term practical experience of research staff the Department of psychiatry and medical psychology RUDN University, Moscow.ResultsTherapy includes antidepressants (AD) - serotonin reuptake inhibitors (SSRIs), antipsychotics and tranquilizers. AD groups of SSRIs reduce most of the symptoms AN and BN - depressive disorders, anxiety, obsessive and compulsive symptoms, episodes of overeating and purifying behavior, suicidal thoughts, and reduce the frequency of relapses. With severe and persistent dysmorphophobia, a high degree of impulsivity, and psychopathic behavior second-generation antipsychotics Quetiapine, Olanzapine, Risperidone and Aripiprazole are used. Benzodiazepine tranquilizers (Lorazepam) are used in small doses and as additional therapy. Data from the European national guidelines for the treatment of AN and BN very different, and the world Federation of societies for biological psychiatry (WFSBP) does not provide specific recommendations at all. There are many reasons for disagreement and lack of specificity regarding drug selection, including the lack of an equally solid evidence base, that reflects the modern state of research on the psychopharmacological treatment of eating disorders.ConclusionsIn General, therapy AN and BN should be comprehensive - psychopharmacotherapy, psychotherapy, diet therapy, social rehabilitation. Treatment should be carried out both in the hospital and on outpatient basis and should be decided individually.Conflict of interestNo significant relationships.

IntroductionAnorexia nervosa (AN) and bulimia nervosa (BN) take one of the first places in the risk of fatal outcome among eating disorders, have a tendency to chronicity and high suicidal risk. Psychopathological basis for AN and BN is a dysmorfofobia or a pathological dissatisfaction with one’s body, characterized by intrusive, overvalued or delusional ideas of physical disability. Dysmorfofobia affects the formation of affective pathology and reduces the life quality.ObjectivesThe study of the correlation between the degree of dissatisfaction with one’s bodies, affective disorders and life quality of patients with AN and BN.Methods130 female patients with AN and BN at the age of 13-44 years (the average age is 18). The disease duration from 6 months to 24 years. Validated Questionnaire image of one’s own body (QIOB) and the Scale of satisfaction with one’s body (SSOB); Hospital anxiety and depression scale (Zigmond A.); Questionnaire for the assessment of life quality (SF-36); Microsoft Excel standard correlation calculation.ResultsDissatisfaction with one’s body based on QIOB and SSOB tests has a significant positive correlation with anxiety and depression, a significant correlation with the psychological component of health, a weak correlation with the physical component of health.ConclusionsDissatisfaction with one’s body or dysmorfofobia of patients with AN and BN significantly affects their affective state and psychological component of life quality which leads to a decrease in functioning up to social maladaptation and disability to social maladjustment. The publication was prepared with the support of the “RUDN University Program 5-100”.